Mayer Brown provided intellectual property counsel to Bristol-Myers Squibb in its $74 billion acquisition of Celgene.

The transaction will create a premier innovative biopharma company with complementary portfolios focused on treating patients with cancer, inflammatory and immunologic disease and cardiovascular disease. The combined company will have expanded capabilities in the areas of small molecule design, biologics, antibody engineering and cell therapy. The transaction is expected to close in the third quarter of 2019.

The Mayer Brown Intellectual Property team included partners Lisa Ferri and Brian Nolan and associate Elliot Choi.

Related Capabilities